Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Total Non-Current Liabilities (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $14.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 126.28% year-over-year to $14.6 million, compared with a TTM value of $14.6 million through Dec 2025, up 126.28%, and an annual FY2025 reading of $14.6 million, up 126.28% over the prior year.
  • Total Non-Current Liabilities was $14.6 million for Q4 2025 at Viemed Healthcare, down from $22.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $22.7 million in Q3 2025 and bottomed at $1.1 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $7.7 million, with a median of $6.4 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities tumbled 79.59% in 2022, then surged 715.81% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $5.3 million in 2021, then crashed by 79.59% to $1.1 million in 2022, then soared by 715.81% to $8.9 million in 2023, then fell by 27.42% to $6.4 million in 2024, then skyrocketed by 126.28% to $14.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for VMD at $14.6 million in Q4 2025, $22.7 million in Q3 2025, and $5.7 million in Q2 2025.